ABEONA THERAPEUTICS INC.
Abeona Therapeutics Inc. (NASDAQ: ABEO) is a commercial-stage biopharmaceutical company focused on developing and commercializing cell and gene therapies for life-threatening genetic diseases. The company's flagship product, ZEVASKYN® (prademagene zamikeracel), received FDA approval in April 2025 as the first and only… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ABEONA THERAPEUTICS INC. does
In the company’s own words
Abeona Therapeutics Inc. (NASDAQ: ABEO) is a commercial-stage biopharmaceutical company focused on developing and commercializing cell and gene therapies for life-threatening genetic diseases. The company's flagship product, ZEVASKYN® (prademagene zamikeracel), received FDA approval in April 2025 as the first and only autologous cell-based gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa, a serious genetic skin disorder caused by deficiency of Type VII collagen. ZEVASKYN® represents a significant advancement for RDEB patients, offering durable wound healing through a single surgical application of gene-modified cellular sheets.
The company manufactures ZEVASKYN® at its current Good Manufacturing Practices facility in Cleveland, Ohio, with treatments administered through a network of qualified treatment centers. As of March 2026, Abeona had activated four qualified treatment centers across the United States and secured broad insurance coverage from commercial insurers, CMS, and all state Medicaid programs.
Beyond ZEVASKYN®, Abeona is developing a pipeline of adeno-associated virus-based gene therapies targeting ophthalmic diseases using its proprietary AIM™ capsid technology platform. Key development programs include ABO-503 for X-linked retinoschisis, ABO-504 for Stargardt disease, and ABO-505 for autosomal dominant optic atrophy. The company licensed its novel AAV capsid technology from the University of North Carolina at Chapel Hill and has established strategic partnerships with academic institutions and biotechnology companies to advance its research and development efforts.
Abeona maintains a robust intellectual property portfolio with patents covering ZEVASKYN®, AAV capsids, manufacturing processes, and treatment methods. The company has out-licensed certain programs, including therapies for Sanfilippo syndrome type A to Ultragenyx Pharmaceutical and previously for Rett syndrome to Taysha Gene Therapies. In 2025, Abeona sold a Priority Review Voucher received upon ZEVASKYN®'s FDA approval for $155 million in gross proceeds. The company's commercial operations focus on establishing treatment centers and engaging healthcare stakeholders to support ZEVASKYN® adoption and market access.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- CLEVELAND, OH
- Fiscal year end
- December
- CIK
- 318306
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ABEONA THERAPEUTICS INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · ABEONA THERAPEUTICS INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ABEONA THERAPEUTICS INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ABEONA THERAPEUTICS INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ABEONA THERAPEUTICS INC.'s last four quarterly filings that the numbers alone won't show?”